Align Technology
ALGN
$169.08
-3.29%
Align Technology Inc. is a global medical device company that designs, manufactures, and markets the Invisalign system of clear aligners and the iTero intraoral scanners, operating within the dental and orthodontic industry. As the dominant player in clear aligners, it controls over 90% of the market and has treated over 14 million patients, leveraging a vast network of trained dental professionals. The current investor narrative centers on a potential value-unlocking catalyst from activist investor Elliott Management, which recently disclosed a large stake, alongside ongoing debates about growth sustainability amid competitive pressures and the company's efforts to expand into new orthodontic segments. The stock has shown resilience with a 31% gain over the past year, but recent momentum has cooled, prompting questions about its near-term trajectory.…
ALGN
Align Technology
$169.08
Related headlines
Investment Opinion: Should I buy ALGN Today?
Rating: Buy. Align Technology is a dominant player in a growing market, and the recent activist involvement could unlock value. The consensus rating is 'Buy' with an average target price of $209.93, implying a 24.1% upside from the current price of $169.16.
Sign up to view all
ALGN 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Align's dominant market position, strong margins, and activist catalyst provide a favorable risk/reward. However, the modest revenue growth and high PEG ratio warrant caution. The stance would be upgraded to high confidence if revenue growth accelerates above 8% or if the company announces a significant share buyback. Conversely, it would be downgraded to neutral if growth falls below 5% or if competitive pressures intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Align Technology's 12-month outlook, with a consensus price target around $209.29 and implied upside of +23.8% versus the current price.
Average Target
$209.29
0 analysts
Implied Upside
+23.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$170 - $240
Analyst target range
The target price range spans from a low of $170.00 to a high of $240.00, with the low target near the current price, suggesting some analysts see limited downside, while the high target implies a 41.9% upside. The wide spread of $70 indicates high uncertainty about the company's future growth and margin trajectory. Recent institutional actions show a mix of reaffirmations and upgrades, with Barclays upgrading from Equal Weight to Overweight in March 2026 and HSBC upgrading from Hold to Buy in February, signaling improving sentiment. However, the presence of a $170 low target suggests that some analysts are cautious about competitive threats and potential margin compression.
Bulls vs Bears: ALGN Investment Factors
Align Technology presents a balanced but slightly bullish case. The company's dominant market position, activist catalyst, and strong forward earnings growth are compelling, but modest revenue growth and high valuation (PEG 51.8) temper enthusiasm. The most important tension is whether the company can accelerate growth beyond the current 6.2% to justify its forward PE of 13.5x; if it does, the stock could re-rate higher, but if growth stagnates, the premium valuation could compress. Currently, the bull case has slightly stronger evidence due to the Elliott catalyst and analyst upgrades, but the risk of disappointment remains.
Bullish
- Dominant market position with 90% share: Align controls over 90% of the clear aligner market, with Invisalign treating over 14 million patients and a network of 230,000 trained professionals. This entrenched leadership provides pricing power and a strong competitive moat, as evidenced by gross margins consistently above 68%.
- Activist catalyst from Elliott Management: Elliott Management's disclosed large stake in March 2026 has sparked optimism for value-unlocking initiatives, such as operational improvements or strategic alternatives. This catalyst could drive the stock toward the analyst high target of $240, a 41.9% upside from the current price.
- Strong forward earnings growth expected: The forward PE of 13.5x versus trailing PE of 27.6x implies the market expects significant earnings growth, with estimated EPS of $15.35 for the next fiscal year. This suggests a forward earnings yield of 7.4%, which is attractive if the company meets its growth projections.
- Healthy balance sheet with minimal debt: Debt-to-equity is a mere 0.028, and the current ratio stands at 1.36, indicating strong liquidity and financial flexibility. This low leverage provides a cushion against economic downturns and allows for potential share buybacks or investments in growth.
Bearish
- Modest revenue growth of 6.2%: Q1 2026 revenue grew only 6.2% year-over-year to $1.04 billion, indicating a mature market and potential saturation. This slow growth may not justify the premium valuation, especially if competition intensifies.
- High valuation with PEG ratio of 51.8: The PEG ratio of 51.8 suggests the stock is significantly overvalued relative to its growth rate, as the trailing PE of 27.6x is high for a company growing revenue in the single digits. This leaves little room for error in execution.
- Recent price momentum has cooled: The stock has declined 6.8% over the past month and 5.4% over the past three months, underperforming the S&P 500 (relative strength -6.96% and -9.11%, respectively). This suggests fading investor enthusiasm and potential further downside.
- Competitive threats from emerging players: While Align dominates, competitors like SmileDirectClub (though bankrupt) and new entrants could erode market share. The low analyst target of $170, near the current price, indicates some analysts see limited upside due to competitive pressures.
ALGN Technical Analysis
Align Technology's stock is in a broad recovery phase, having climbed 31.1% over the past year, yet it currently trades at $169.16, which is 84.4% of its 52-week range (between $122.00 and $200.44). This positioning near the upper half of the range suggests a constructive long-term trend, but the stock is off its highs, indicating some loss of momentum. The 52-week low of $122.00 provides a strong support level, while the high of $200.44 represents a key resistance zone that bulls need to reclaim to signal a resumption of the uptrend.
Beta
1.65
1.65x market volatility
Max Drawdown
-39.7%
Largest decline past year
52-Week Range
$122-$200
Price range past year
Annual Return
+23.5%
Cumulative gain past year
| Period | ALGN Return | S&P 500 |
|---|---|---|
| 1m | -8.7% | +2.8% |
| 3m | +0.2% | +4.2% |
| 6m | -9.9% | +11.3% |
| 1y | +23.5% | +21.5% |
| ytd | +8.4% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALGN Fundamental Analysis
Align Technology's revenue trajectory shows steady growth, with Q1 2026 revenue of $1.04 billion, up 6.2% year-over-year, and a sequential increase from $995.7 million in Q3 2025. The company's clear aligner segment generated $794.3 million, while scanners and services contributed $200.9 million, indicating the core aligner business remains the primary growth driver. However, growth has been modest, with quarterly revenue fluctuating between $977.9 million and $1.05 billion over the past two years, suggesting a mature market and potential saturation in some regions.
Quarterly Revenue
$1.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
70.8%
Latest Quarter
Free Cash Flow
$686093000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALGN Overvalued?
Given Align Technology's positive net income of $112.8 million in Q1 2026, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 27.6x, while the forward PE is 13.5x, implying the market expects significant earnings growth, likely driven by margin expansion and operational efficiencies. The gap between trailing and forward PE suggests a forward earnings yield of 7.4%, which is attractive if the company can deliver on its growth projections.
PE
27.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Align's financial health is solid, with minimal debt (debt-to-equity 0.028) and positive free cash flow of $686 million TTM. However, revenue growth is modest at 6.2% YoY, and the company's net margin of 10.2% is relatively thin for a premium brand, indicating potential margin pressure from competition or rising costs. The high PE of 27.6x leaves little room for earnings misses, and any slowdown in aligner sales could trigger a de-rating. Additionally, the company's reliance on the Invisalign brand for the majority of revenue (76% in Q1) creates concentration risk if consumer preferences shift.